Similarly, while recurrent intravitreal injections of the monoclonal anti-VEGF antibody ranibizumab (Lucentis) is the standard of care for age-related macular degeneration where the majority of patients show visual stabilization [8], isolated cases of macular ischemia and persistent elevation in intraocular pressure following treatment have been reported [45], [46] and the long term effects of drug resistance, tolerance or ancillary effects in targeting this pathway have yet to be addressed. This evidence concerns the gene VEGFA and age-related macular degeneration.